Literature DB >> 21395483

Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers.

Kevin Smith1, Michael Hopp, Gill Mundin, Simon Bond, Paul Bailey, Jo Woodward, Karuppan Palaniappan, Ann Church, Marie Limb, Alyson Connor.   

Abstract

OBJECTIVES: This exploratory study in healthy volunteers investigated the effect of single doses of oxycodone on gastrointestinal (GI) transit time and the degree to which a single dose of naloxone reverses the oxycodone-induced effect.
METHODS: Fifteen healthy male volunteers received: oxycodone 10 and2 0 mg, oxycodone/naloxone 10/5 and 20/10 mg (all as prolonged release tablets) and placebo. Each dose was radiolabelled and administered with a capsule containing radiolabelled resin (surrogate for GI contents).
RESULTS: Scintigraphic analysis showed that 20 mg oxycodone significantly increased colon arrival time (mean 7.19 vs 5.15 h for placebo, p = 0.0159). Mean colon arrival time for oxycodone/naloxone 20/10 mg (5.16 h) was similar to placebo, although the difference between oxycodone/naloxone 20/10 mg versus oxycodone 20 mg was not significant (p = 0.0653). Colonic geometric centre analysis showed a significant increase in mean time for the resin to reach the colon following oxycodone 10 and 20 mg compared with placebo (increases of 5.3 and 8.8 h). There was no significant effect of naloxone at the lower dose; however, oxycodone/naloxone 20/10 mg significantly reduced mean colonic transit time by 2.1 h (p = 0.0376).
CONCLUSION: A single dose of oxycodone 20 mg significantly prolonged GI transit time but this effect was reduced by co-administration of naloxone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21395483     DOI: 10.1517/13543784.2011.563236

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  23 in total

Review 1.  Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.

Authors:  Celeste B Burness; Gillian M Keating
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

2.  Opioid/naloxone prolonged release combinations for opioid induced constipation.

Authors:  Shailendra Kapoor
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 3.  Opioid-induced constipation: advances and clinical guidance.

Authors:  Alfred D Nelson; Michael Camilleri
Journal:  Ther Adv Chronic Dis       Date:  2016-01-25       Impact factor: 5.091

4.  Critical Scrutiny Needed.

Authors:  Thorsten Nickel
Journal:  Dtsch Arztebl Int       Date:  2018-01-08       Impact factor: 5.594

Review 5.  Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.

Authors:  Michael Camilleri; Anthony Lembo; David A Katzka
Journal:  Clin Gastroenterol Hepatol       Date:  2017-05-19       Impact factor: 11.382

Review 6.  Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice.

Authors:  Ana Fernández-Montes; Guillermo de Velasco; Santiago Aguín; Cristina Farriols; María Guirado-Risueño; Vanessa G Jerviz-Guía; María Victoria Baeza-Nadal; Rodolfo Chicas-Sett; José Luis Fírvida; Francisco García-Navalón; Patricia Martín; Carmen Perezagua-Marín; Dulce Rodríguez; Joan Santamaría; Tamara Saurí; Manuel Cobo
Journal:  Curr Treat Options Oncol       Date:  2021-02-26

Review 7.  Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.

Authors:  Wojciech Leppert
Journal:  Drug Des Devel Ther       Date:  2015-04-16       Impact factor: 4.162

Review 8.  Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.

Authors:  Roberto De Giorgio; Furio Massimino Zucco; Giuseppe Chiarioni; Sebastiano Mercadante; Enrico Stefano Corazziari; Augusto Caraceni; Patrizio Odetti; Raffaele Giusti; Franco Marinangeli; Carmine Pinto
Journal:  Adv Ther       Date:  2021-06-04       Impact factor: 3.845

9.  Opioid and chronic non-cancer pain.

Authors:  Sameer Gupta; Robert Atcheson
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2013-01

10.  The place of oxycodone/naloxone in chronic pain management.

Authors:  Wojciech Leppert
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.